TFII.TO -1.7C 0.13MU -51.63CRWD 5.64PANW 6.15SNOW -4.82V -0.14MAL.TO -0.14
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

25.01
+0.10 (0.40%)
as of Jul 31, 2026, 8:00:00 pm Market Open.
581 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
DON'T BUY

Pfizer Inc(PFE)

Nov 02, 2004
An excellent company, but a poor stock. The whole pharmaceutical sector has been under pressure for 2/3 years.
Photo of Ian NakamotoIan Nakamoto
Owned
Unlock Rating
$28.70

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 29, 2004
SHould do well if Bush wins the election.
Photo of Alison DeansAlison DeansUnlock Rating
$28.95

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 27, 2004
Pharmaceuticals are cheaper than he has ever seen them. Cheap. Trading at low multiples.
Photo of John ZechnerJohn Zechner
No
Unlock Rating
$29.04

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 26, 2004
30% discount between their model price and current stock price.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$28.33

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 22, 2004
Has been beaten up. Has all the good things going for it according to analysts. Strong cash flow.
Photo of Robert StovallRobert Stovall
Owned
Unlock Rating
$27.74

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 20, 2004
Has had a very disappointing performance. Big pharmas have some issues facing them with regards to generic drugs. An extremely good company. Ran into problems because of their recall of Vioxx.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$28.30

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Oct 12, 2004
Has dropped in sympathy with Merk and their recall of Vioxx as they have a similar product which is a big seller. Pharmaceutical industry as a whole has been hurt by generics and lagging R&D. Could drop further. All money is made in the US.
Photo of Paul Harris, CFAPaul Harris, CFA
No
Unlock Rating
$29.86

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 07, 2004
Thinks its been oversold. Big pharmas have been in the dog house for at least 5 years.
Photo of Brian Acker, CABrian Acker, CA
Owned
Unlock Rating
$29.99

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Oct 01, 2004
Interested in companies that have very good earnings growth and visibility. Have a pipeline that is not being valued appropriately.
Photo of Mary FarrellMary Farrell
Owned
Unlock Rating
$30.97

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 24, 2004
Best value in the market is in quality names. Best pharmaceutical company in the world. Just hasn't gone anywhere. New products are going into the pipeline.
Photo of Nicholas SargenNicholas Sargen
Owned
Unlock Rating
$29.66

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Sep 13, 2004
(A Top Pick Dec 29/03. Down 9%.) Have bought more on the dips. Health care industry in the US has suffered for the last 2 years. Showing strong revenue growth.
Photo of John Sinkins, CFAJohn Sinkins, CFA
Owned
Unlock Rating
$32.13

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 10, 2004
A lot of drug stocks have been under pressure. All of the US drug companies are in a favorable position of having reasonable growth prospects.
Photo of Ray SteeleRay Steele
No
Unlock Rating
$31.86

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Sep 08, 2004
Feels the US drug companies will continue to have tough sledding because of generics. This company is better equipped to fight that. Growth through acquisition.
Photo of Andrew McCreathAndrew McCreath
No
Unlock Rating
$32.77

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 03, 2004
Best U.S. drug company. They have new products that were just introduced. Own Lipridor, the largest drug.
Photo of Jackee PrattJackee Pratt
Owned
Unlock Rating
$32.55

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
TRADE

Pfizer Inc(PFE)

Aug 30, 2004
Long-term: it is a good investment.
Photo of John ZechnerJohn ZechnerUnlock Rating
$32.46

Stock price when the opinion was issued

$25.01

As of Jul 31, 2026. Market Open.

biotechnologypharmaceutical
Showing 706 to 720 of 885 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

EOG 3.18$148.69
SLB 0.68$49.59
SHEL 1.47$91.98
AAPL -24.52$308.91
AMZN 36.08$271.58
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

Today's Top Picks

TFII.TO -1.7$13.38
C 0.13$132.45
MU -51.63$823.03
CRWD 5.64$190.86
PANW 6.15$331.83

Popular Articles

Latest Sell Signals

AAPL -24.52$308.91
AAPL -24.52$308.91
AAPL -24.52$308.91
T.TO -1.7$13.38
CCA.TO -1.1$59.1

Most Recent Experts

Amy Raskin, CIO, Chevy Chase Trust

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Stephanie Link, Chief investment strategist, Hightower

Stephanie Link, Chief investment strategist, Hightower

Hightower

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Brianne Gardner

Brianne Gardner

Raymond James

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like